查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1754321

2025 年至 2033 年 HIV 藥物市場規模、佔有率、趨勢及預測（按藥物類別、配銷通路和地區分類）

HIV Drugs Market Size, Share, Trends and Forecast by Drug Class, Distribution Channel, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球愛滋病藥物市場規模為328.5億美元。展望未來， IMARC Group估計，到2033年，市場規模將達到450.7億美元，2025-2033年期間的複合年成長率為3.40%。目前，北美佔據市場主導地位，到2024年將佔據超過45.7%的市場。由於人們的認知和預防工作不斷加強、全球愛滋病毒/愛滋病的盛行率不斷上升，以及各種旨在開發更有效、更易獲得的抗逆轉錄病毒療法的研發項目，愛滋病藥物市場佔有率正在穩步成長。

各行各業都意識到利用海量結構化和非結構化資料進行決策、提升客戶體驗和改善營運的重要性。巨量資料應用的日益成長、人工智慧和機器學習技術的創新以及雲端運算應用領域的不斷拓展，進一步推動了這一趨勢。此外，各行各業對數據驅動決策的需求不斷成長，也推動了愛滋病藥物的需求。此外，數位轉型專案的蓬勃發展以及應對競爭壓力和不斷變化的市場需求對即時分析的需求，也是市場成長的主要驅動力。

美國是市場的關鍵顛覆者，其驅動力來自各行各業廣泛的數位轉型舉措，而分析技術對於營運最佳化和策略規劃至關重要。國防部門擴大採用先進技術，為愛滋病藥物市場的成長開闢了新的成長途徑。例如，2024年7月，美國國防部與新加坡國防部簽署了資料、分析和人工智慧合作意向書 (SOI)。該意向書部署了一種全面的技術合作方法，使雙方國防機構能夠研究各種方法，並探討如何快速、大規模地利用資料、分析和人工智慧能力的最佳實踐。

HIV藥物市場趨勢：

愛滋病毒/愛滋病日益流行

全球愛滋病毒/愛滋病疫情仍然是一個關鍵的公共衛生議題。一份產業報告顯示，截至2021年，全球約有3,800萬人感染愛滋病毒。這種日益成長的感染率直接推動了對愛滋病毒藥物的需求。隨著新病例不斷出現，尤其是在預防措施有限的地區，對有效治療方案的需求日益增加。愛滋病毒的高傳播率，尤其是在撒哈拉以南非洲以及亞洲和東歐的部分地區，需要持續並更多地提供抗逆轉錄病毒療法 (ART)，這仍然是愛滋病毒治療的基石。

治療方面的進步

近年來，愛滋病毒治療方案取得了顯著進展，推動了愛滋病毒藥物市場的成長。高效抗逆轉錄病毒療法 (HAART) 的開發，結合了多種抗逆轉錄病毒藥物，徹底改變了愛滋病毒的治療。這些進展不僅提高了愛滋病毒藥物的有效性，也減少了副作用，從而提高了患者的依從性和治療效果。整合酶抑制劑等新型藥物的推出以及長效注射劑的開發，進一步擴展了治療選擇，滿足了不同患者的需求和偏好。例如，2024 年，吉利德在格拉斯哥愛滋病毒大會上分享了一年兩次服用利那卡帕韋預防愛滋病毒的完整 III 期 PURPOSE 2 試驗結果。研究表明，利那卡帕韋可將愛滋病毒感染率降低 96%，優於特魯瓦達 (Truvada)。這些進展提高了治療效果，也增強了患者的依從性，為愛滋病毒藥物市場的持續成長奠定了基礎。

提高患者意識

患者意識的提高和診斷率的提高是推動愛滋病藥物市場的主要因素。例如，在印度，國家愛滋病控制計畫 (NACP) 在 2020-21 年期間進行了約 4,800 萬次愛滋病毒檢測，其中包括對孕婦的 2,480 萬次檢測。在 2022-23 年的前六個月，進行了約 3,100 萬次愛滋病毒檢測，預測表明，在整個 2022-23 年期間將進行超過 6000 萬次檢測，這是該計劃啟動以來的最高水平。檢測數量的增加導致確診並隨後尋求治療的人數增加。截至 2022 年 9 月，印度約有 162.4 萬名愛滋病毒感染者 (PLHIV) 正在接受抗逆轉錄病毒 (ARV) 治療，比前一年增加了 11 萬人。公共衛生運動和教育措施提高了人們對愛滋病毒/愛滋病的認知，減少了恥辱感，並鼓勵更多人接受檢測。早期診斷技術的進步也提高了愛滋病毒的檢出率，從而增加了尋求治療的人數。診斷率的上升，加上持續改善愛滋病毒檢測的努力，尤其是在高發病率地區，持續推動了對有效愛滋病毒藥物的需求。

聯合療法日益受到關注

聯合療法已成為愛滋病毒治療的標準，涉及使用多種抗逆轉錄病毒藥物來增強療效和預防抗藥性。固定劑量組合（FDC）的開發和批准簡化了治療方案，提高了依從性和患者預後。製藥公司越來越注重開發這些聯合療法，它們比單一療法有幾個優勢，包括減少藥物和提高患者依從性。領先的製藥公司吉利德科學報告其聯合療法Biktarvy銷售強勁。 2024年第四季，Biktarvy的銷售額達到38億美元，比前一年成長21%。這一成長使吉利德本季的愛滋病毒藥物總收入達到76億美元。醫療保健提供者和患者對聯合療法的偏好日益成長，這是愛滋病毒藥物市場前景樂觀的關鍵因素。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球愛滋病藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 價格分析
  • 市場區隔：依藥品類別
  • 市場區隔：按配銷通路
  • 市場區隔：按地區
  • 市場預測
  • SWOT分析
  • 價值鏈分析
  • 波特五力分析

第6章：市場區隔：依藥品類別

  • 核苷逆轉錄酶抑制劑
  • 多類別組合產品
  • 蛋白酶抑制劑
  • HIV整合酶鏈轉移抑制劑
  • 非核苷逆轉錄酶抑制劑
  • 進入抑制劑 - CCR5 輔助受體拮抗劑
  • 融合抑制劑及其他

第7章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

第8章：市場區隔：依地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

第9章：HIV藥物製造過程

  • 產品概述
  • 原料需求
  • 製造過程
  • 關鍵成功因素與風險因素

第10章：競爭格局

  • 市場結構
  • 市場區隔：按關鍵參與者
  • 關鍵參與者簡介
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • ViiV Healthcare
    • AbbVie
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Cipla Limited
    • Daiichi Sankyo
    • Emcure
    • Hetero Drugs
    • Mylan
Product Code: SR112025A953

The global HIV drugs market size was valued at USD 32.85 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 45.07 Billion by 2033, exhibiting a CAGR of 3.40% during 2025-2033. North America currently dominates the market, holding a significant market share of over 45.7% in 2024. The HIV drugs market share is experiencing steady growth due to the increasing awareness and prevention efforts, growing prevalence of HIV/AIDS across the globe, and ongoing various research and development initiatives focused on more effective and accessible antiretroviral therapies.

Various organizations are identifying the significance of leveraging vast volumes of structured and unstructured data to make decisions, enhance customer experience, and enhance operations. Growing use of big data, innovations in AI and machine learning technologies, and broadening use areas of cloud computing have further increased this trend. Additionally, increased demand for data-driven decision-making across various industries is driving the HIV drugs demand. Besides, the growth in digital transformation projects and the demand for real-time analytics to respond to competitive pressures and changing market needs are the major drivers of the growth of the market.

The United States stands out as a key market disruptor, driven by widespread digital transformation initiatives across diverse sectors where analytics is pivotal for operational optimization and strategic planning. The increasing initiatives for implementing advanced technologies in the defense sector are opening new growth avenues for the HIV drugs market growth. For instance, in July 2024, The United States Department of Defense signed a Statement of Intent (SOI) for data, analytics, and artificial intelligence cooperation with the Singapore Ministry of Defense. The SOI deploys a holistic method for technological collaboration, allowing both defense establishments to examine approaches and discuss the best practices for leveraging data, analytics, and AI capabilities at speed and scale.

HIV Drugs Market Trends:

Growing Prevalence of HIV/AIDS

The global HIV/AIDS epidemic remains a critical public health issue, with approximately 38 million people living with HIV worldwide as of 2021, according to an industry report. This increased prevalence directly drives the demand for HIV drugs. As new cases continue to emerge, especially in regions with limited access to preventive measures, the need for effective treatment options intensifies. The high transmission rate of HIV, particularly in sub-Saharan Africa and certain parts of Asia and Eastern Europe, necessitates sustained and increased availability of antiretroviral therapy (ART), which remains the cornerstone of HIV treatment.

Advancements in Treatments

Recent years have witnessed significant advancements in HIV treatment regimens, contributing to the growth of the HIV drugs market. The development of highly active antiretroviral therapy (HAART), which combines multiple antiretroviral drugs, has revolutionized HIV treatment. These advancements have not only improved the effectiveness of HIV drugs but also reduced side effects, leading to better patient adherence and outcomes. The introduction of newer drug classes like integrase inhibitors and the development of long-acting injectables have further expanded treatment options, catering to diverse patient needs and preferences. For example, in 2024, Gilead shared complete Phase 3 PURPOSE 2 trial results on twice-yearly lenacapavir for HIV prevention at HIV Glasgow. The research demonstrated lenacapavir lowered HIV infections by 96%, beating Truvada. These developments increase treatment effectiveness and also enhance patient compliance, underpinning ongoing HIV drugs market growth.

Increasing Awareness Among Patients

Rising awareness and diagnostic rates among patients represent the primary factor driving the HIV drugs market. In India, for instance, the National AIDS Control Programme (NACP) conducted approximately 48 million HIV tests in the 2020-21 period, including 24.8 million tests among pregnant women. In the first six months of 2022-23, around 31 million HIV tests were undertaken, with projections indicating that more than 60 million tests would be conducted during the entire 2022-23 period-the highest since the program's inception. This increase in testing has led to a rise in the number of individuals diagnosed and subsequently seeking treatment. As of September 2022, approximately 1.624 million people living with HIV (PLHIV) in India were on antiretroviral (ARV) treatment, an increase of 110,000 from the previous year. Public health campaigns and educational initiatives have increased the understanding of HIV/AIDS, reducing stigma and encouraging more people to get tested. Early and improved diagnostic techniques have also contributed to higher detection rates of HIV, subsequently increasing the number of individuals seeking treatment. This rise in diagnosis, coupled with ongoing efforts to improve HIV testing, particularly in regions with high prevalence rates, continues to fuel the demand for effective HIV medications.

Rising Focus on Combination Therapies

Combination therapies have become a standard in HIV treatment, involving the use of multiple antiretroviral drugs to enhance efficacy and prevent drug resistance. The development and approval of fixed-dose combinations (FDCs) have simplified treatment regimens, improving adherence and patient outcomes. Pharmaceutical companies are increasingly focusing on developing these combination therapies, which offer several advantages over monotherapy, including reduced pill burden and improved patient compliance. Gilead Sciences, a leading pharmaceutical company, reported robust sales of its combination therapy, Biktarvy. In the fourth quarter of 2024, Biktarvy achieved sales of USD 3.8 billion, marking a 21% increase from the previous year. This growth contributed to Gilead's total HIV drug revenue of USD 7.6 billion for the quarter. The growing preference for combination therapies among healthcare providers and patients is a key factor providing a positive HIV drugs market outlook.

HIV Drugs Industry Segmentation:

Analysis by Drug Class:

  • Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Products
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • Fusion Inhibitors and Others

Nucleoside reverse transcriptase inhibitors lead the market with around 43.2% of market share in 2024. NRTIs, also known as nucleoside analogs, are a crucial class of HIV drugs. They inhibit the action of reverse transcriptase, an enzyme the virus uses to replicate its genetic material. NRTIs are often included as a backbone in HIV treatment regimens due to their effectiveness and safety. They are widely used as a first-line therapy, either alone or in combination with other drug classes, making them the largest segment in the HIV drugs market.

Multi-class combination products refer to antiretroviral therapies that combine drugs from different classes. These combinations are designed to target HIV from multiple angles, reducing the risk of resistance development and increasing treatment efficacy. They offer convenience by simplifying the regimen for patients and are often prescribed when NRTIs alone are insufficient.

Protease inhibitors (PIs) interfere with the protease enzyme, necessary for HIV maturation and replication. PIs are a vital part of combination therapies and have been instrumental in reducing HIV-related deaths. They are used in conjunction with other drug classes to suppress viral replication effectively.

Integrase strand transfer inhibitors (INSTIs) block the integration of viral genetic material into the host cell's DNA, preventing viral replication. INSTIs have gained prominence due to their potent antiviral activity and favorable side-effect profiles. They are commonly used in first-line regimens and in treatment-experienced patients.

NNRTIs are another class of HIV drugs that target reverse transcriptase but do so differently from NRTIs. They bind to the enzyme and inhibit its activity. NNRTIs are often part of combination therapies and are especially useful in cases where resistance to other drug classes has developed.

CCR5 co-receptor antagonists block the CCR5 receptor on the surface of immune cells, preventing HIV from entering and infecting these cells. They are typically used in patients who are CCR5-tropic, meaning their virus uses the CCR5 co-receptor for entry.

Fusion inhibitors work by preventing the virus from fusing with the host cell membrane, thus inhibiting viral entry. This class of drugs is less commonly used than others due to their complex administration (usually by injection).

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Hospital pharmacies lead the market with around 49.5% of market share in 2024. Hospital pharmacies constitute the largest segment in the HIV drugs market, primarily due to their role as essential providers of antiretroviral therapies to inpatients and outpatients living with HIV/AIDS. These pharmacies operate within healthcare institutions, including public and private hospitals, clinics, and specialty HIV treatment centers. They offer a wide range of HIV medications, ensuring access to the latest antiretroviral therapies for patients. Hospital pharmacies play a crucial role in medication management, counseling, and monitoring, contributing significantly to patient adherence and treatment outcomes. With a direct link to healthcare providers, hospital pharmacies are pivotal in the comprehensive care and management of HIV/AIDS patients.

Retail pharmacies, including independent drugstores and chain pharmacies, form another vital segment in the HIV drugs market. They serve as accessible points of care for individuals seeking prescription medications, including antiretroviral drugs. Retail pharmacies provide convenience and privacy for patients picking up their HIV medications. They play a critical role in supporting medication adherence through counseling and refill reminders. The retail segment is especially important for patients in urban and suburban areas who may not access hospital-based care regularly.

Online pharmacies have gained prominence as a convenient and discrete source of HIV medications. This segment caters to individuals who prefer the convenience of ordering their antiretroviral drugs online and having them delivered to their doorstep. Online pharmacies offer a wide selection of HIV medications, often at competitive prices. They may also provide telemedicine services, enabling patients to consult with healthcare professionals remotely. The online pharmacy segment has seen significant growth, particularly in regions with robust e-commerce infrastructure, and it serves as an option for individuals who face barriers to traditional pharmacy access.

Regional Analysis:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 45.7%. North America dominates the global HIV drugs market due to its well-developed healthcare infrastructure, high awareness about HIV/AIDS, and access to advanced antiretroviral therapies. The region is characterized by extensive research and development activities, a large patient population, and significant government funding for HIV/AIDS programs. Furthermore, the presence of major pharmaceutical companies in North America contributes to the market's growth. The focus here is on innovative treatments, combination therapies, and efforts to reduce new infections through comprehensive prevention strategies.

Europe is a substantial market for HIV drugs, characterized by a well-regulated healthcare system and access to state-of-the-art treatments. The region has made progress in reducing HIV transmission rates, but it continues to face challenges related to stigma and late diagnosis. The market in Europe is driven by increasing awareness, comprehensive healthcare coverage, and collaborations between healthcare providers and pharmaceutical companies to improve patient outcomes. Additionally, research into long-acting therapies and preventive measures like PrEP contributes to the market's development.

The Asia Pacific region is witnessing rapid growth in the HIV drugs market due to its large and diverse population, including many individuals living with HIV. This segment faces unique challenges, such as varying healthcare infrastructure, economic disparities, and culturally diverse populations. Increased efforts to expand access to treatment, raise awareness, and reduce new infections are driving market growth. Generic medications and government initiatives to combat HIV/AIDS play a significant role in the Asia Pacific market. Moreover, collaborations with international organizations and NGOs are enhancing the region's response to the HIV epidemic.

Latin America has a growing HIV drugs market, driven by the expanding healthcare infrastructure and increased access to treatment and prevention programs. The region faces challenges related to inequality and limited access to healthcare services in some areas. However, initiatives to improve healthcare coverage, raise awareness, and expand access to antiretroviral therapies are driving market growth. Collaboration between governments, pharmaceutical companies, and non-profit organizations is critical to addressing the HIV/AIDS epidemic in Latin America.

The Middle East and Africa represent a diverse and challenging market for HIV drugs. While access to treatment has improved in some countries, significant disparities persist due to economic and healthcare infrastructure differences. The region faces cultural and social stigma related to HIV/AIDS, which can hinder diagnosis and treatment. Nonetheless, efforts to expand access to medications, increase awareness, and promote preventive measures are ongoing. Partnerships with international organizations and global health initiatives are crucial in addressing the unique challenges in the Middle East and Africa.

Competitive Landscape:

Key players in the global HIV drugs market are actively engaged in several strategic initiatives. They are focusing on research and development to innovate and improve existing antiretroviral therapies, aiming for more convenient dosing regimens, fewer side effects, and enhanced treatment outcomes. These companies are also expanding their product portfolios by developing new drugs and combination therapies. Additionally, they are collaborating with governments, NGOs, and healthcare providers to increase access to HIV medications in resource-limited regions and to implement preventive measures. Furthermore, these pharmaceutical giants are investing in awareness campaigns and education to reduce HIV stigma and promote early diagnosis and treatment.

The report provides a comprehensive analysis of the competitive landscape in the HIV drugs market with detailed profiles of all major companies, including:

  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • ViiV Healthcare
  • AbbVie
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Cipla Limited
  • Daiichi Sankyo
  • Emcure Pharmaceuticals
  • Hetero Drugs
  • Mylan N.V

Key Questions Answered in This Report

  • 1.How big is the HIV drugs market?
  • 2.What is the future outlook of HIV drugs market?
  • 3.What are the key factors driving the HIV drugs market?
  • 4.Which region accounts for the largest HIV drugs market share?
  • 5.Which are the leading companies in the global HIV drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global HIV Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Price Analysis
  • 5.5 Market Breakup by Drug Class
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast
  • 5.9 SWOT Analysis
    • 5.9.1 Overview
    • 5.9.2 Strengths
    • 5.9.3 Weaknesses
    • 5.9.4 Opportunities
    • 5.9.5 Threats
  • 5.10 Value Chain Analysis
    • 5.10.1 Overview
    • 5.10.2 Research and Development
    • 5.10.3 Raw Material Procurement
    • 5.10.4 Manufacturing
    • 5.10.5 Marketing
    • 5.10.6 Distribution
    • 5.10.7 End-Use
  • 5.11 Porters Five Forces Analysis
    • 5.11.1 Overview
    • 5.11.2 Bargaining Power of Buyers
    • 5.11.3 Bargaining Power of Suppliers
    • 5.11.4 Degree of Competition
    • 5.11.5 Threat of New Entrants
    • 5.11.6 Threat of Substitutes

6 Market Breakup by Drug Class

  • 6.1 Nucleoside Reverse Transcriptase Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Multi-Class Combination Products
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Protease Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 HIV Integrase Strand Transfer Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Fusion Inhibitors and Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia Pacific
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Middle East and Africa
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Latin America
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

  • 9.1 Product Overview
  • 9.2 Raw Material Requirements
  • 9.3 Manufacturing Process
  • 9.4 Key Success and Risk Factors

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Market Breakup by Key Players
  • 10.3 Profiles of Key Players
    • 10.3.1 Boehringer Ingelheim International GmbH
    • 10.3.2 Merck & Co., Inc.
    • 10.3.3 ViiV Healthcare
    • 10.3.4 AbbVie
    • 10.3.5 F. Hoffmann-La Roche Ltd.
    • 10.3.6 Teva Pharmaceutical Industries Ltd.
    • 10.3.7 Bristol-Myers Squibb
    • 10.3.8 Gilead Sciences, Inc.
    • 10.3.9 Johnson & Johnson
    • 10.3.10 Cipla Limited
    • 10.3.11 Daiichi Sankyo
    • 10.3.12 Emcure
    • 10.3.13 Hetero Drugs
    • 10.3.14 Mylan

List of Figures

  • Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: HIV Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2024
  • Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 7: Global: HIV Drugs Industry: SWOT Analysis
  • Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
  • Figure 9: Global: HIV Drugs Industry: Porter's Five Forces Analysis
  • Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million USD), 2019 & 2024
  • Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2025-2033
  • Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million USD), 2019 & 2024
  • Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million USD), 2025-2033
  • Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million USD), 2019 & 2024
  • Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million USD), 2025-2033
  • Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million USD), 2019 & 2024
  • Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million USD), 2025-2033
  • Figure 32: North America: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Europe: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
  • Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

  • Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: HIV Drugs Manufacturing: Raw Material Requirements
  • Table 6: Global: HIV Drugs Market: Competitive Structure
  • Table 7: Global: HIV Drugs Market: Key Players